hip hip jorg guid increas
thesi updat result continu trend strong
wholesal print least rel last
guid take-up unexpect treat much upsid
came line tax share count nice see
manag cost effort also bear fruit allow
medic ebit reiter furthermor construct
commentari cordi tsa transit help de-risk
path offer profit upsid cushion
expect renew headwind share
write remain sidelin particularli given
macro uncertainti rebat increasingli posit
dispos distributor overal reiter
rate pt
revenu overal pharma offset
lower medic revenu growth gross
margin came slightli correspond off-set
ultim higher revenu drop way caus
us increas ep estim forecast
ep call note pleas click link
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
msd revenu growth pharma
pharma m-hsd
medic approxim flat larg due fx
brand inflat came within expect rang
exceed mm lt goal least mm
revers mm accru
revers mm accru
occur assess amount
power partnership grow custom
pharmaci daili deliveri
improv brand volum
posit impact cost-reduct initi
make progress strateg initi
exit last major tsa asia
accret goal track
integr progress expect
path profit growth end
stabil track
servic level fill rate
inventori
profit impact spot market
see improv spot price take
time impact
cost tsa exit
victor crawford new ceo pharma segment
benefit pure growth specialti
littl inflat built rest year given
much come januari
inflat came within expect rang
earli comment next year
continu move contract non-conting
almost point
cordi revenu trend posit past sever quarter
fx small headwind quarter impact
raw materi continu headwind rest year
trend right direct alway long lag
spot price impact
harbor chang expand
unlik get wors rest year
support effort lower price custom
work administr
way industri provid rebat
alreadi complex charge-back system
custom supplier
dont see chang margin trend go
gross net chang
go comment margin
downstream price also attach wac natur hedg
short term
work chang contract accommod
potenti chang wac quickli
convers manufactur posit
renegoti would like keep dollar though
expect inflat juli happen
higher januari
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america
articl articl
time dissemin februari
analyst elizabeth anderson suzi yoon ross muken primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani
issuer part research analyst compens directli relat specif recommend view
research report
